MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Phase 1
Completed
Conditions
Lymphoma
Interventions
Biological: therapeutic autologous lymphocytes
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation (PBSCT)
First Posted Date
2005-10-27
Last Posted Date
2015-03-26
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
15
Registration Number
NCT00244946
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2005-10-21
Last Posted Date
2017-09-28
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
44
Registration Number
NCT00242996
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2005-10-13
Last Posted Date
2017-11-06
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
59
Registration Number
NCT00238368
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy
First Posted Date
2005-10-06
Last Posted Date
2018-03-01
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
98
Registration Number
NCT00233987
Locations
🇺🇸

Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States

🇺🇸

Associates in Womens Health, PA - North Review, Wichita, Kansas, United States

🇺🇸

Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States

and more 50 locations

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Phase 2
Completed
Conditions
Testicular Neoplasms
Interventions
Drug: epirubicin
Procedure: high-dose and autologous stem cell transplantation
Drug: paclitaxel
Drug: etoposide
Drug: ifosfamide
Drug: carboplatin
First Posted Date
2005-10-04
Last Posted Date
2011-02-25
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
50
Registration Number
NCT00231582
Locations
🇫🇷

Hôpital TENON, Service d'Oncologie Médicale, Paris, France

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

First Posted Date
2005-09-23
Last Posted Date
2014-08-27
Lead Sponsor
Stanford University
Target Recruit Count
45
Registration Number
NCT00225173
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2005-09-22
Last Posted Date
2013-06-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
15
Registration Number
NCT00217503
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2005-09-22
Last Posted Date
2016-03-16
Lead Sponsor
Nasser Hanna, M.D.
Target Recruit Count
243
Registration Number
NCT00216125
Locations
🇺🇸

Community Regional Cancer Center, Indianapolis, Indiana, United States

🇺🇸

US Oncology, Houston, Texas, United States

🇺🇸

Siteman Cancer Center, St. Louis, Missouri, United States

and more 12 locations

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

Phase 2
Conditions
De Novo Akute Myeloid Leukemia (AML)
Secondary Acute Myeloid Leukemia (AML)
Refractory Anemia With Excess of Blasts in Transformation
First Posted Date
2005-09-21
Last Posted Date
2005-11-18
Lead Sponsor
Hannover Medical School
Target Recruit Count
200
Registration Number
NCT00209833
Locations
🇩🇪

Hannover Medical School, Hannover, Germany

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Phase 3
Conditions
Lymphoma, Mantle-Cell
Interventions
First Posted Date
2005-09-21
Last Posted Date
2012-09-10
Lead Sponsor
European Mantle Cell Lymphoma Network
Target Recruit Count
360
Registration Number
NCT00209222
Locations
🇫🇷

Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France

🇩🇪

German Low Grade Study Group (Glsg), Munich, Germany

🇵🇱

The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland

© Copyright 2025. All Rights Reserved by MedPath